Pfizer (PFE) stock slips as a Phase 3 trial failure for its sickle cell disease therapy inclacumab marks the latest setback ...

The Food and Drug Administration could pull Pfizer's coronavirus vaccine emergency authorization for children under age 5.

In the latest setback for Pfizer's sickle cell anemia treatments, experimental drug inclacumab failed to meet the main goal ...

Pfizer said on Tuesday its cancer drug Padcev, in combination with Merck's Keytruda, significantly improved survival rates in ...

Pfizer's experimental drug to treat sickle cell anemia failed to meet the main goal in a late stage trial, the drugmaker said ...

The landscape of COVID-19 vaccinations for children is shifting in the US. How will this affect the upcoming virus season?

Pfizer (PFE 0.06%) has been a terrible investment over the past three years. Revenue and earnings have generally moved in the wrong direction, as the company has been unable to fo ...

Several workers reported symptoms of being exposed to a substance and some were taken to the hospital. The state is ...

Pfizer (NYSE: PFE) is a case in point, with its forward dividend yield of 7%. Although the stock is a favorite for many ...

Pfizer beats Q2 estimates with $14.7B revenue and $0.78 EPS. Management showed extreme confidence by raising full-year EPS ...

We recently published 10 Stocks Jim Cramer Discussed As He Questioned Official Data. Pfizer Inc. (NYSE:PFE) is one of the ...

Pfizer Inc. (NYSE:PFE) discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the ...